Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.70 |
| ▸ | CTSS | P25774 | 3/20 | 0.70 |
| ▸ | CTSK | P43235 | 2/20 | 0.70 |
| ▸ | CTSB | P07858 | 1/20 | 0.70 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.62 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.62 |
| ▸ | TACR1 | P25103 | 2/20 | 0.61 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16601896 | 0.95 | CTSL (0.67) | CTSLCTSSCTSKCTSBSIRT2 | |
| SCHEMBL10802560 | 0.93 | CTSL (0.73) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL9113871 | 0.92 | CTSL (0.73) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL30185946 | 0.90 | CTSL (0.64) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL17643540 | 0.90 | CTSL (0.76) | CTSLCTSSCTSKCTSBTACR1 | |
| SCHEMBL18822607 | 0.87 | CTSL (0.77) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL14598350 | 0.87 | CTSL (0.66) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL9306413 | 0.87 | CTSL (0.64) | CTSLCTSSCAPN1CAPN2SIRT2 | |
| SCHEMBL14903029 | 0.87 | MEN1 (0.56) | CTSLCTSSCTSKCTSBSIRT2 | |
| SCHEMBL3615382 | 0.87 | CTSL (0.65) | CTSLCTSSCTSKCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020220023-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | FIVE ELEVEN PHARMA INC. (US) | 2020-10-29 | — | — | WO | disclosed |